BARRETT’S ESOPHAGUS
AT A GLANCE
|
Definition |
Metaplastic replacement of the normal stratified squamous epithelium of the distal esophagus by specialized intestinal-type columnar epithelium, usually as a consequence of chronic gastroesophageal reflux. |
|
Major association |
Chronic gastroesophageal reflux disease (GERD). |
|
Major cancer risk |
Esophageal adenocarcinoma (EAC). Site lower 1/3 of esophagus |
|
Major risk factors |
Male sex, age >50 years, obesity/central adiposity, smoking, chronic GERD and first-degree family history of BE/EAC. |
|
Endoscopic documentation |
High-definition white-light endoscopy + chromoendoscopy; document landmarks and Prague C&M extent. |
|
Biopsy strategy |
Target visible abnormalities first; then structured four-quadrant biopsies (Seattle protocol). |
|
Nondysplastic BE |
Daily PPI + risk/length-based surveillance; routine ablation is not recommended. Risk of EAC 0.2%-0.4%, risk varies with length |
|
Confirmed Low Grade Dysplasia |
Risk of EAC – 0.9%-1%/yr. EET is favored as per AGA 2024 but surveillance remains acceptable an alternative after shared decision making. |
|
Confirmed High Grade Dysplasia |
Endoscopic eradication therapy (EET) is preferred over surveillance. |
|
Visible neoplasia |
Endoscopic resection first; then ablate residual Barrett’s mucosa when appropriate. |
1. DEFINITION AND TERMINOLOGY
Barrett’s esophagus (BE) is an acquired metaplastic condition in which the normal distal esophageal squamous mucosa is replaced by columnar epithelium.
American College of Gastroenterology (ACG) definition, BE requires endoscopically visible columnar mucosa extending at least 1 cm above the gastroesophageal junction (GEJ) together with intestinal metaplasia in biopsies from the tubular esophagus.
The European Society of Gastrointestinal Endoscopy (ESGE) uses the same practical 1-cm threshold and recommends no routine biopsy or surveillance for an irregular Z-line/columnar-lined esophagus measuring <1 cm when no visible lesion is present.
2. PATHOGENESIS AND NATURAL HISTORY
The squamous epithelium of the distal esophagus is repeatedly exposed to gastric acid and duodenogastroesophageal refluxate in susceptible individuals. Chronic injury, inflammation and epithelial repair are associated with replacement by columnar-type epithelium.
CHRONIC REFLUX / MUCOSAL INJURY
↓
Columnar metaplasia
↓
Intestinal metaplasia
↓
Genetic / epigenetic abnormalities
↓
IND → LGD → HGD → EAC
IND- Indefinite Dysplasia, LGD – Low grade dysplasia, HGD- High grade dysplasia, EAC- Esophageal Adenocarcinoma
Most patients with nondysplastic BE will not develop EAC; therefore, routine ablation of nondysplastic BE is not justified.
3. RISK FACTORS
|
Risk factor |
|
Chronic GERD |
|
Male sex |
|
Age >50 years |
|
Obesity / central adiposity |
|
Current or prior smoking |
|
First-degree family history |
|
White race |
|
Hiatal hernia |
4. WHO SHOULD UNDERGO SCREENING?
Routine screening of every patient with GERD is not recommended. ACG suggests considering a single screening EGD (esophageal gastroduodenoscopy) in patients with chronic GERD plus at least three additional risk factors.
• Male sex
• Age >50 years
• White race
• Tobacco smoking
• Obesity
• First-degree family history of BE or EAC
Alarm symptoms such as dysphagia, odynophagia, GI bleeding, iron-deficiency anemia, weight loss or persistent vomiting are indications for diagnostic endoscopy independent of routine screening criteria.
After a negative screening examination, routine repeat screening is not recommended. Exception : severe erosive esophagitis, where underlying BE may be obscured; repeat EGD after healing should be considered.
5. CLINICAL PRESENTATION
BE itself is usually asymptomatic. Most patients are diagnosed during endoscopy performed for GERD symptoms or another upper-GI indication.
• Heartburn
• Acid regurgitation
• Nocturnal reflux
• Retrosternal burning
• Chronic cough or other extra-esophageal symptoms in selected patients
Symptoms do not reliably predict the presence or extent of BE. A patient may have BE despite minimal current reflux symptoms.
6. ENDOSCOPIC DIAGNOSIS AND DOCUMENTATION
Barrett’s examination should identify and document the diaphragmatic hiatus, GEJ/top of gastric folds, squamocolumnar junction (Z-line), proximal extent of columnar mucosa and every visible abnormality.
Current AGA surveillance guidance emphasizes high-definition white-light endoscopy combined with chromoendoscopy.
Endoscopy documentation:
|
Landmarks |
Diaphragmatic hiatus, GEJ/top of gastric folds and Z-line. |
|
Extent |
Prague C&M classification. |
|
Visible abnormalities |
Nodularity, ulceration, depression, irregular surface/vascular pattern or focal discoloration. |
|
Photodocumentation |
Landmarks, BE segment and visible lesions; ESGE recommends approximately one image per cm of BE length. |
|
Inspection quality |
ESGE recommends at least 1 minute of inspection per cm of BE length during surveillance. |
ESGE: European society of Gastrointestinal Endoscopy
7. PRAGUE C&M CLASSIFICATION
The Prague C&M system standardizes the extent of Barrett’s mucosa.
• C = circumferential extent: maximum length of circumferential Barrett’s mucosa.
• M = maximum extent: most proximal extent of Barrett’s mucosa, including tongues.
Example: C2M5 means 2 cm of circumferential BE with maximum proximal extension to 5 cm.
Prague measurement is less reproducible for segments <1 cm, reinforcing the importance of the 1-cm threshold for defining and surveilling BE.
8. THE IRREGULAR Z-LINE: WHAT TO DO
|
Finding |
Action |
|
Normal Z-line |
No biopsy solely for the appearance of a normal Z-line. |
|
Irregular Z-line / columnar mucosa <1 cm, no visible lesion |
No routine biopsies and no Barrett’s surveillance. |
|
≥1 cm suspected Barrett’s |
Careful documentation + systematic biopsy sampling. |
|
Any visible lesion |
Targeted biopsy or, when appropriate, endoscopic resection regardless of segment length. |
9. HISTOLOGY AND BIOPSY PROTOCOL
Intestinal metaplasia may be patchy. Inadequate sampling can therefore produce a false-negative result.
During screening/surveillance, visible abnormalities should be sampled first. Structured random biopsies are then obtained using a Seattle-type protocol.
|
Visible abnormality |
Targeted biopsy or endoscopic resection first, depending on appearance and suspicion. |
|
Nondysplastic BE surveillance |
Four-quadrant systematic biopsies approximately every 2 cm. |
|
Known/suspected dysplasia |
Four-quadrant biopsies approximately every 1 cm, plus targeted sampling. |
|
Short segment where 8 biopsies are feasible |
ACG suggests at least 8 biopsies for suspected BE to reduce sampling error. |
The pathology report should clearly distinguish nondysplastic intestinal metaplasia from indefinite dysplasia, low-grade dysplasia, high-grade dysplasia and carcinoma.
10. PATHOLOGY CATEGORIES
|
NDBE |
Intestinal metaplasia without dysplasia. |
PPI + surveillance; no routine EET. |
|
Indefinite for dysplasia |
Atypia cannot confidently be classified as dysplasia, often because of inflammation. |
Optimize reflux control + expert review/reassessment. |
|
LGD |
Confirmed low-grade neoplastic change. |
EET or close surveillance based on presence of other risk factors. |
|
HGD |
Advanced dysplasia with high risk of progression. |
EET preferred. |
|
EAC |
Invasive adenocarcinoma. |
Stage and treat according to depth/risk; visible early lesions generally require endoscopic resection first. |
11. MANAGEMENT OVERVIEW
SUSPECTED BARRETT’S
↓
HD white light + chromoendoscopy
↓
Prague C&M + visible lesion assessment
↓
Targeted lesions + structured biopsies
↓
HISTOLOGY
↓
NDBE → PPI + surveillance
IND → optimize acid suppression + repeat expert assessment
LGD → expert pathology confirmation → EET or close surveillance
HGD → EET
VISIBLE NEOPLASIA → RESECTION FIRST → histology-directed therapy
NDBE- Non dysplastic BE, LGD- Low Grade Dysplasia, HGD- High Grade Dysplasia
12. MANAGEMENT OF BARRETT’S ESOPHAGUS
|
CATEGORY |
MANAGEMENT |
|
NDBE |
No routine EET. Daily PPI; increase to twice-daily only for reflux symptoms, esophagitis or other clinical indications. Surveillance ACG 2022: ESGE 2023: AGA 2025: |
|
INDEFINITE FOR DYSPLASIA (IND) |
Expert GI pathology review → optimize acid suppression/heal esophagitis → repeat high-quality EGD with systematic biopsies, commonly within 3–6 months. Persistent dysplasia is managed according to confirmed histology and risk. AGA 2025: confirmed IND should undergo repeat expert endoscopic/pathologic assessment rather than immediate EET; if IND persists, surveillance is continued according to the dysplasia pathway. |
|
LOW-GRADE DYSPLASIA (LGD) |
Expert GI pathology confirmation is essential. AGA 2024: EET is favored over surveillance; surveillance remains reasonable after shared decision-making because the mortality benefit is uncertain and EET phas procedure-related harms. ACG 2022: EET is preferred, although surveillance is an acceptable alternative. ESGE 2023: Offer ablation when LGD is confirmed on ≥2 separate endoscopies, both confirmed by a second experienced pathologist. If surveillance is chosen repeat endoscopy at 6 months, 12 months, then annually. |
|
HIGH-GRADE DYSPLASIA (HGD) |
Substantial progression risk; occult cancer may already be present. Confirm with expert GI pathology and perform high-quality endoscopic assessment at an expert center. Resect visible lesions, then ablate remaining flat BE. EET is preferred over surveillance; surveillance alone is not the default when definitive endoscopic therapy is feasible. |
|
ENDOSCOPIC ERADICATION THERAPY (EET) |
Core sequence: VISIBLE NEOPLASTIC LESION → ENDOSCOPIC RESECTION → histopathology (grade + depth + margins + lymphovascular invasion) → if endoscopically curable/appropriate → ABLATION OF RESIDUAL FLAT BARRETT’S → confirm complete eradication + surveillance. RFA is commonly used; cryotherapy is an established alternative when selected or when RFA is unsuitable/unsuccessful. Endpoints: complete eradication of neoplasia (CEN) and, when intended, complete eradication of intestinal metaplasia (CEIM). |
14. ENDOSCOPIC RESECTION: EMR VS ESD
|
EMR (Endoscopic mucosal resection) |
Preferred for most visible Barrett’s neoplastic lesions; provides tissue for accurate histologic staging. |
|
ESD (Endoscopic submucosal dissection ) |
Consider for large/bulky lesions, lesions suspicious for deeper submucosal invasion, complex/depressed morphology, or lesions in which en-bloc resection and precise assessment of depth and margins are particularly important. |
AGA 2024: EMR or ESD may be selected according to lesion characteristics; most visible neoplastic lesions can be managed with EMR, while ESD is reserved for selected lesions where en-bloc resection or precise assessment of deeper invasion is particularly important.
15. EARLY ESOPHAGEAL ADENOCARCINOMA
T1a disease is confined to the mucosa. Appropriately selected intramucosal EAC can often be treated endoscopically.
T1b disease invades the submucosa and requires careful assessment of depth, differentiation and lymphovascular invasion.
|
Feature |
Implication |
|
T1a / intramucosal |
Endoscopic therapy is often curative in appropriately selected lesions. |
|
T1b superficial, low-risk features |
May be considered for endoscopic management in expert multidisciplinary settings in selected patients. |
|
>500 μm submucosal invasion |
High-risk feature; consider additional staging and surgery/systemic therapy according to multidisciplinary assessment. |
|
Poor differentiation |
High-risk feature. |
|
Lymphovascular invasion |
High-risk feature for nodal disease. |
Deep submucosal invasion, poor differentiation or lymphovascular invasion should trigger multidisciplinary staging and discussion of additional therapy.
16. SURVEILLANCE AFTER ENDOSCOPIC ERADICATION THERAPY
EET does not eliminate the need for follow-up. Recurrent or metachronous Barrett’s and dysplasia can occur.
|
Baseline indication for EET |
Post-EET surveillance: practical framework |
|
LGD |
AGA 2024: surveillance at years 1 and 3 after CEIM, then return to the NDBE surveillance strategy. ESGE 2023: 1, 3 and 5 years after successful EET |
|
HGD / EAC |
HGD / T1a EAC — AGA 2024: surveillance at 3, 6 and 12 months after CEIM, then annually. ESGE 2023: 1, 2, 3, 4, 5, 7 and 10 years after successful EET. |
Because AGA and ESGE use different post-EET schedules, the treating expert center should follow a clearly documented protocol and account for baseline pathology rather than mixing interval from different guidelines.
17. CLINICAL ALGORITHMS
A. SCREENING ALGORITHM
CHRONIC GERD
↓
Assess additional risk factors
↓
≥3 additional risk factors → consider screening EGD
↓
HD EGD + landmarks + Prague assessment
↓
Suspected BE ≥1 cm → systematic biopsy
B. SURVEILLANCE ALGORITHM
ESTABLISHED BE
↓
<1 cm? → no routine surveillance if no neoplasia
1–<3 cm NDBE → ACG/ESGE: 5-year Interval
≥3–<10 cm NDBE → 3-year interval
≥10 cm → expert-center surveillance
Dysplasia → expert pathology + dysplasia pathway
C. DYSPLASIA ALGORITHM
DYSPLASIA ON BIOPSY
↓
EXPERT GI PATHOLOGY CONFIRMATION
↓
IND → optimize acid suppression + repeat assessment
LGD → EET vs close surveillance after shared decision-making
HGD → EET
VISIBLE LESION → RESECTION FIRST
18. REFERENCES
1. Harrison’s Principles of Internal Medicine. 22nd Edition. 2025. GERD, Barrett’s metaplasia and upper gastrointestinal tract cancers
2. Wani S, Zhou MJ, Sawas T, et al. AGA Clinical Practice Guideline on Surveillance of Barrett’s Esophagus. Gastroenterology. 2025;169:1184–1231.
3. Rubenstein JH, Sawas T, Wani S, et al. AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett’s Esophagus and Related Neoplasia. Gastroenterology. 2024;166:1020–1055. doi:10.1053/j.gastro.2024.03.019.
4. Shaheen NJ, et al. Diagnosis and Management of Barrett’s Esophagus: An Updated ACG Guideline. Am J Gastroenterol. 2022;117:559–587.
5. Weusten BLAM, Bisschops R, Dinis-Ribeiro M, et al. Diagnosis and management of Barrett esophagus: ESGE Guideline. Endoscopy. 2023;55:1124–1146. doi:10.1055/a-2176-2440.